Resiquimod

Resiquimod
Clinical data
Routes of; administration	Topical
ATC code	none;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol;
CAS Number	144875-48-9 ;
PubChem CID	159603;
IUPHAR/BPS	5051;
ChemSpider	140330 ;
UNII	V3DMU7PVXF;
ChEMBL	ChEMBL383322 ;
CompTox Dashboard (EPA)	DTXSID7040603 ;
Chemical and physical data
Formula	C17H22N4O2
Molar mass	314.389 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O;
	InChI InChI=1S/C17H22N4O2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19) ; Key:BXNMTOQRYBFHNZ-UHFFFAOYSA-N ;
	(what is this?) (verify)

Resiquimod (R-848) is a drug that acts as an immune response modifier, and has antiviral and antitumour activity. It is used as a topical gel^[1] in the treatment of skin lesions^[2] such as those caused by the herpes simplex virus^[3]^[4] and cutaneous T cell lymphoma,^[5] and as an adjuvant to increase the effectiveness of vaccines.^[6] In an animal disease model, systemic administration of resiquimod-loaded nanoparticles has been shown to improve response rates to cancer immunotherapy with a checkpoint inhibitor through stimulation of tumor-associated macrophages.^[7] It has several mechanisms of action, being both an agonist for toll-like receptor 7 and 8,^[8] and an upregulator of the opioid growth factor receptor.^[9] On 28 April 2016, orphan designation (EU/3/16/1653) was granted by the European Commission to Galderma R&D, France for resiquimod to be used in the treatment of cutaneous T-cell lymphoma.^[10]

Quick Facts Clinical data, Routes ofadministration ...

Close

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

Resiquimod

See also

References

Wikiwand - on